On March 8, 2021 Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, reported that it will be participating in the following virtual investor conferences (Press release, Applied DNA Sciences, MAR 8, 2021, View Source [SID1234576203]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

March 9 – 10, 2021 – Dr. James A. Hayward, president and CEO, will present a company overview at the H.C. Wainwright Global Life Sciences Virtual Conference. Dr. Hayward and Beth Jantzen, chief financial officer, will also hold virtual investor meetings. Dr. Hayward’s pre-recorded presentation will be available for viewing beginning March 9 at 7:00 A.M. (ET). The presentation will also be available on Applied DNA’s website (link);
March 15 – 17, 2021 – Dr. Hayward will participate on a virtual panel at Roth Capital Markets’ 33rd Annual Conference titled ‘Therapeutics Against SARS-CoV-2 – Viral variants Will Not Fade Away’. The panel is scheduled for March 15, 2021 at 12:00pm ET and will be available to all Conference attendees, as well as on Applied DNA’s website (link). Management will also hold virtual investor meetings;
March 17 – 19, 2021 – Dr. Hayward will present at the Inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC. The presentation will be available to all registered participants of the conference (link) on March 17th – 19th and will be posted on Applied DNA’s website (link) after March 19.

On March 8, 2021 IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, reported that it will hold a conference call and webcast on Wednesday, March 17, 2021 at 8:00 a.m. Eastern Time to discuss the Company’s 2020 fourth quarter and full year financial and operational results (Press release, IMV, MAR 8, 2021, View Source [SID1234576202]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (international) using the conference ID: 8998652.

Other interested parties will be able to access the live audio webcast at this link: View Source The webcast will be recorded and will then be available on the IMV website for 30 days following the call.

On March 8, 2021 Eli Lilly and Company (NYSE:LLY) reported that it will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021 (Press release, Eli Lilly, MAR 8, 2021, View Source [SID1234576200]). Patrik Jonsson, senior vice president, president of Lilly USA and chief customer officer, will participate in a virtual fireside chat at 9:45 a.m., Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On March 8, 2021 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported that Anixa’s Chief Executive Officer, Dr. Amit Kumar, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC (Press release, Anixa Biosciences, MAR 8, 2021, View Source [SID1234576199]). The conference will take place on March 17 and 18 from 9:00 am-5:00 pm ET featuring roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers both domestically and internationally.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During this virtual conference, Anixa will present along with other important voices in the biotech industry. Dr. Kumar will provide an overview of Anixa’s business and an update on the Company’s programs. To attend the conference, sign up to become an M-Vest member here: https://www.m-vest.com/events/2021-emerging-growth-virtual-conference.

On March 8, 2021 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on disruptive, target-directed Natural Killer (NK) cell engager immunotherapy technologies (TriKE) for cancer, reported preclinical results for its ROR1 TriKE product candidate as a prospective therapy for the treatment of prostate cancer (Press release, GT Biopharma, MAR 8, 2021, View Source [SID1234576198]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tyrosine kinase transmembrane receptor ROR1 has recently been shown to be overexpressed on certain cancer cells, and appears to play a functional role in promoting migration/invasion and influencing the metastatic potential of various solid tumor cancers. Targeting ROR1 on cancer cells with TriKE and redirecting NK cells to attack and kill cancer cells expressing ROR1, could result in a therapeutic treatment that limits the metastatic potential and invasiveness of certain solid tumor cancers.

The ROR1 TriKE was evaluated in several preclinical models of prostate cancer, and was found to be effective at promoting NK cell killing of multiple prostate cancer cells including LnCAP, C4-2, PC-3, DU-145, VCaP and 22RV1. Significant NK cell activation and interferon gamma (IFNγ) production was also observed as a result of TriKE engagement and activation of the NK cell.

"We are pleased to report our ROR1 TriKE has passed this important preclinical milestone, and demonstrated effectiveness in promoting redirected and target-specific killing by NK cells," said Anthony J. Cataldo, GT Biopharma’s Chairman and Chief Executive Officer. "We plan to evaluate the ROR1 TriKE in additional IND-enabling preclinical studies with the goal of transitioning to a Phase I/II clinical trial."